TY - JOUR T1 -重复剂量布地奈德/福莫特罗与沙丁胺醇治疗成人哮喘的比较:随机交叉试验JF -欧洲呼吸杂志》乔和J - 10.1183/13993003.02309 -2021欧元SP - 2102309 AU -卡恩斯,年AU -布鲁斯,Pepa AU -威廉姆斯,马修盟——Doppen Marjan AU -黑色,梅丽莎盟——因此,马克AU -比斯利,理查德Y1 - 2022/01/01 UR - //www.qdcxjkg.com/content/early/2022/01/20/13993003.02309 - 2021. -文摘N2 -目的确定比较支气管扩张剂,系统性beta2-agonist,稳定期哮喘患者反复服用沙丁胺醇200µg和布地奈德/福莫特罗200/6µg时的心血管和不良反应。方法:这项开放标签、交叉、单中心对照试验，将成人哮喘患者随机分为两种不同的治疗方案:在t=0、30、60、90 min时，通过MDI给予沙丁胺醇200µg，然后在t=120、140、160和420 min时，雾化吸入沙丁胺醇2.5 mg;或布地奈德/福莫特罗200/6µg一次经Turbuhaler驱动，在t= 0,30,60,90 min，两次驱动，在t=120, 140, 160和420 min。主要指标为180 min后的FEV1。次要结局包括FEV1、血钾、心率和不良事件的重复测量。结果在39例随机患者中，有2例在沙丁胺醇首次干预后因不良事件(QTCF延长和T波异常)退出。沙丁胺醇和布地奈德/福莫特罗方案随机分组后180 min与基线FEV1的平均(sd)变化分别为0.71 (0.46)L, N=38和0.58 (0.45)L, N=37;平均(sd)成对差异为−0.10 (0.40)L, N=37，基于模型的估计差异(95% CI)为−0.12(−0.25至0.02)L, p=0.088。在主要的次要分析中，沙丁胺醇导致30至240分钟的FEV1显著增加，但在360和420分钟时FEV1较低。 Salbutamol resulted in a significantly lower serum potassium, and a higher heart rate and number of adverse events.Conclusion The comparative bronchodilator responses of repeated administration of salbutamol 200 µg dose−1 and budesonide/formoterol 200/6 µg differed depending on the time of measurement. Salbutamol caused greater systemic beta2-agonist and cardiovascular effects and more adverse events.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of Interest: RB has received research funding from Genentech, Astra Zeneca and Health Research Council New Zealand and personal fees from AstraZeneca, Cipla, Avillion and Theravance all outside the submitted work. All other authors have nothing to disclose outside of the funding for this study. ER -